Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 11—November 2021

Mutations Associated with SARS-CoV-2 Variants of Concern, Benin, Early 2021

Anna-Lena Sander1, Anges Yadouleton1, Edmilson F. de Oliveira Filho, Carine Tchibozo, Gildas Hounkanrin, Yvette Badou, Praise Adewumi, Keke K. René, Dossou Ange, Salifou Sourakatou, Eclou Sedjro, Melchior A. J. Aïssi, Hinson Fidelia, Mamoudou Harouna Djingarey, Michael Nagel, Wendy Karen Jo, Andres Moreira-Soto, Christian Drosten, Olfert Landt, Victor Max Corman, Benjamin Hounkpatin, and Jan Felix DrexlerComments to Author 
Author affiliations: Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany (A.-L. Sander, E.F. de Oliveira Filho, W.K. Jo, A. Moreira-Soto, C. Drosten, V.M. Corman, J.F. Drexler); Ecole Normale Supérieure de Natitingou, Natitingou, Benin (A. Yadouleton); Université Nationale des Sciences, Technologies, Ingénierie et Mathématiques (UNSTIM), Cotonou, Benin (A. Yadouleton); Laboratoire des Fièvres Hémorragiques Virales du Benin, Cotonou (A. Yadouleton, C. Tchibozo, G. Hounkanrin, Y. Badou, P. Adewumi); Ministry of Health, Cotonou (K.K. René, D. Ange, S. Sourakatou, B. Hounkpatin); Conseil National de Lutte contre le VIH-Sida, la Tuberculose, le Paludisme, les IST et les Epidémies, Cotonou (E. Sedjro, M.A. Joël Aïssi, H. Fidelia); World Health Organization Regional Office for Africa, Health Emergencies Programme, Brazzaville, Democratic Republic of the Congo (M.H. Djingarey); Deutsche Gesellschaft für Internationale Zusammenarbeit, Bonn, Germany (M. Nagel); German Centre for Infection Research (DZIF), associated partner Charité-Universitätsmedizin Berlin, Berlin (C. Drosten, V.M. Corman, J.F. Drexler); TIB Molbiol Syntheselabor GmbH, Berlin (O. Landt)

Main Article

Table 1

Screened mutations, potential effects, and occurrence in severe acute respiratory syndrome coronavirus 2 variants, Benin, 2021

SNP assay
Spike protein variation
Potential effects
SARS-CoV-2 variant
B.1.1.7 Alpha†
B.1.351 Beta†
P.1 Gamma†
B.1.617.2 Delta†
del HV69/70 Immune escape and enhanced viral infectivity (4) x x
E484K Antibody resistance (4) x x x x x
Increased transmission (4)



Higher mortality rates‡


Antibody resistance (4)

4 K417T No data x
K417N Immune escape (5) x
P681H No data x
P681R No data x

*SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SNP single-nucleotide polymorphism. †Variants of concern according to the World Health Organization. ‡G. Hahn et al., unpub. data,

Main Article

  1. Warmbrod  KL, West  R, Frieman  M, George  D, Martin  E, Rivers  C. Staying ahead of the variants: policy recommendations to identify and manage current and future variants of concern. Baltimore (MD): Johns Hopkins Center for Health Security; 2021 Feb 16 [cited 2021 May 28].
  2. Jo  WK, Drosten  C, Drexler  JF. The evolutionary dynamics of endemic human coronaviruses. Virus Evol. 2021;7:veab020.
  3. Sander  AL, Yadouleton  A, Moreira-Soto  A, Tchibozo  C, Hounkanrin  G, Badou  Y, et al. An observational laboratory-based assessment of SARS-CoV-2 molecular diagnostics in Benin, Western Africa. MSphere. 2021;6:e0097920. DOIPubMedGoogle Scholar
  4. Harvey  WT, Carabelli  AM, Jackson  B, Gupta  RK, Thomson  EC, Harrison  EM, et al.; COVID-19 Genomics UK (COG-UK) Consortium. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19:40924. DOIPubMedGoogle Scholar
  5. Zhou  D, Dejnirattisai  W, Supasa  P, Liu  C, Mentzer  AJ, Ginn  HM, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021;184:23482361.e6. DOIPubMedGoogle Scholar
  6. Sanyang  B, Kanteh  A, Usuf  E, Nadjm  B, Jarju  S, Bah  A, et al. COVID-19 reinfections in The Gambia by phylogenetically distinct SARS-CoV-2 variants-first two confirmed events in west Africa. Lancet Glob Health. 2021;9:e9057. DOIPubMedGoogle Scholar
  7. Yadouleton  A, Sander  AL, Moreira-Soto  A, Tchibozo  C, Hounkanrin  G, Badou  Y, et al. Limited specificity of serologic tests for SARS-CoV-2 antibody detection, Benin, Western Africa. Emerg Infect Dis. 2021;27:2020. DOIPubMedGoogle Scholar
  8. Liu  J, Liu  Y, Xia  H, Zou  J, Weaver  SC, Swanson  KA, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021;596:2735. DOIPubMedGoogle Scholar
  9. Kollmann  TR. Variation between populations in the innate immune response to vaccine adjuvants. Front Immunol. 2013;4:81. DOIPubMedGoogle Scholar
  10. Polack  FP, Thomas  SJ, Kitchin  N, Absalon  J, Gurtman  A, Lockhart  S, et al.; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:260315. DOIPubMedGoogle Scholar

Main Article

1These first authors contributed equally to this article.

Page created: August 09, 2021
Page updated: October 19, 2021
Page reviewed: October 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.